Skip to content

Effect and safety evaluation of Anrikefon combined with propofol in painless gastrointestinal endoscopy

Effect and safety evaluation of Anrikefon combined with propofol in painless gastrointestinal endoscopy

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2600118604
Enrollment
Unknown
Registered
2026-02-09
Start date
2026-02-09
Completion date
Unknown
Last updated
2026-02-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Painless gastrointestinal endoscopy anesthesia

Interventions

Group H:In group H, 1ug/kg of Enrique was slowly injected 15min before anesthesia induction for 2min.
Group P:Group P was given 0.1ml/kg saline 15min before anesthesia induction, and the injection time was 2min.

Sponsors

Jiangxi Provincial People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who underwent painless gastrointestinal endoscopy in our hospital, ASAI-II grade, aged 18-74 years, BMI 18-28 kg/m^2.

Exclusion criteria

Exclusion criteria: 1. Serious heart, liver, kidney, lung and other important organ diseases. 2. Severe electrolyte disorder, difficult airway. 3. Abnormal thyroid function. 4. Long-term use of analgesic drugs, psychotropic drugs, anticoagulants and alcohol abuse. 5. Have a history of abnormal surgery anesthesia recovery and anesthesia drug allergy. 6. Pregnant women or participated in other drug trials within 3 months. 7. Allergic to propofol, Anrikefon and its components.

Design outcomes

Primary

MeasureTime frame
Total induced dose of propofol, frequency and dosage of propofol supplementation, and total dosage of propofol;;Abdominal distension and abdominal pain score 15min after waking up.;incidence of hypoxemia (spo 2 < 90%);

Secondary

MeasureTime frame
Induction time; Awakening time; Out-of-room time;Body movement and coughing during operation;The incidence of subclinical respiratory depression (SpO 2 < 95%);Injection pain, bradycardia and hypotension;;postoperative nausea and vomiting, postoperative headache and dizziness.;

Countries

China

Contacts

Public ContactLuo Heguo

Department of Anesthesiology, Jiangxi Provincial People's Hospital

1596450316@qq.com+86 138 0703 5516

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 19, 2026